Asensus Surgical, Inc. ( ASXC Quick Quote ASXC - Free Report) is scheduled to release first-quarter 2021 results on May 11, after the closing bell. In the last reported quarter, the company reported a loss of 9 cents per share, narrower than the Zacks Consensus Estimate of a loss of 11 cents per share. Q1 Estimates
Currently, the Zacks Consensus Estimate for first-quarter revenues is pegged at $1.60 million, suggesting growth of 166.7% from the year-ago reported figure. The consensus estimate for the bottom line stands at a loss of 7 cents per share.
Factors to Note
Asensus Surgical is likely to have witnessed revenue growth in first-quarter 2021, driven by strength in product and services revenues.
In March 2021, Asensus Surgical received an additional FDA clearance for the Senhance Surgical System that enables for indication expansion in general surgery in the United States. In February, the company collaborated with the Amsterdam Skills Centre (ASC) in the Netherlands for surgical training. This site will cater to surgeons and staff across Europe with basic and advanced training on the Senhance Surgical System. The ASC will also offer Asensus Surgical with a world-class facility that will drive engagement for European surgeons in technology and clinical development studies.
In January, Asensus Surgical received CE Mark for the ISU, thereby allowing machine vision capabilities on the Senhance Surgical System. This approval will help Senhance digital laparoscopic programs in Europe to gain access to this new technology, which in turn will help the company pioneer surgical innovation utilizing augmented intelligence.
In December 2020, the company’s Senhance Surgical System received its registration certificate by the Russian medical device regulatory agency – Roszdravnadzor – that will enable the sale and utilization of the same across the Russian Federation. These developments are likely to have contributed to the to-be-reported quarter’s performance. What Our Quantitative Model Suggests
Per our proven model, a combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see. Earnings ESP: Asensus Surgical has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #3. Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
National Vision Holdings, Inc. ( EYE Quick Quote EYE - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here. American Well Corporation ( AMWL Quick Quote AMWL - Free Report) has an Earnings ESP of +9.44% and a Zacks Rank of 3. Evolus, Inc. ( EOLS Quick Quote EOLS - Free Report) has an Earnings ESP of +3.36% and a Zacks Rank of 3. +1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond. Click here to download this report FREE >>